CN101469348B - In situ hybridization detection kit for early carcinoma of prostate, detecting method and use thereof - Google Patents
In situ hybridization detection kit for early carcinoma of prostate, detecting method and use thereof Download PDFInfo
- Publication number
- CN101469348B CN101469348B CN2008100422578A CN200810042257A CN101469348B CN 101469348 B CN101469348 B CN 101469348B CN 2008100422578 A CN2008100422578 A CN 2008100422578A CN 200810042257 A CN200810042257 A CN 200810042257A CN 101469348 B CN101469348 B CN 101469348B
- Authority
- CN
- China
- Prior art keywords
- hybridization
- prostate
- gene
- pcadm
- marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 40
- 201000001514 prostate carcinoma Diseases 0.000 title claims description 22
- 238000007901 in situ hybridization Methods 0.000 title abstract description 8
- 238000000034 method Methods 0.000 title description 21
- 238000009396 hybridization Methods 0.000 claims abstract description 47
- 239000000523 sample Substances 0.000 claims abstract description 34
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 32
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 31
- 239000003550 marker Substances 0.000 claims abstract description 22
- 239000012747 synergistic agent Substances 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 238000011065 in-situ storage Methods 0.000 claims description 20
- 238000012360 testing method Methods 0.000 claims description 18
- 230000002285 radioactive effect Effects 0.000 claims description 8
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 6
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 4
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 4
- 229960005156 digoxin Drugs 0.000 claims description 4
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 4
- 229930003756 Vitamin B7 Natural products 0.000 claims description 3
- 239000011735 vitamin B7 Substances 0.000 claims description 3
- 235000011912 vitamin B7 Nutrition 0.000 claims description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 34
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 9
- 239000000758 substrate Substances 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 238000013016 damping Methods 0.000 description 39
- 239000012530 fluid Substances 0.000 description 39
- 239000007788 liquid Substances 0.000 description 35
- 206010028980 Neoplasm Diseases 0.000 description 24
- 201000011510 cancer Diseases 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 17
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000007899 nucleic acid hybridization Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 6
- 238000013399 early diagnosis Methods 0.000 description 6
- 235000011194 food seasoning agent Nutrition 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 101150032458 Amacr gene Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 210000002249 digestive system Anatomy 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 101150068332 KIT gene Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 3
- 238000002059 diagnostic imaging Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- VOZKAJLKRJDJLL-UHFFFAOYSA-N 2,4-diaminotoluene Chemical compound CC1=CC=C(N)C=C1N VOZKAJLKRJDJLL-UHFFFAOYSA-N 0.000 description 2
- 102100040410 Alpha-methylacyl-CoA racemase Human genes 0.000 description 2
- 108010044434 Alpha-methylacyl-CoA racemase Proteins 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 208000004965 Prostatic Intraepithelial Neoplasia Diseases 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000012151 immunohistochemical method Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000001625 seminal vesicle Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 201000010653 vesiculitis Diseases 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000227135 Atrina Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 101000617550 Dictyostelium discoideum Presenilin-A Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000882982 Homo sapiens CDK5 regulatory subunit-associated protein 3 Proteins 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 241000973497 Siphonognathus argyrophanes Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000009668 clonal growth Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- -1 developer Substances 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
Images
Abstract
The invention relates to an in-situ hybridization detection reagent kit for early prostate cancer, which comprises a hybridization probe, a marker and a synergistic agent, wherein the hybridization probe has a sequence shown in SEQ ID NO.1. The invention also provides an in-situ hybridization detection method for a PCADM-1 gene, which comprises the following steps: a, the hybridization probe in the reagent kit contacts RNA to be detected in a substrate to form a hybridization complex; and b, the hybridization complex obtained in step a is detected. The invention also provides application of the reagent kit to preparation of a medicine for detecting early diseases of prostate cancer. The reagent kit has the advantages that the reagent kit has the characteristics of high sensitivity and strong specificity. The detection method has convenient and simple operation, and can be universally used and promoted in district hospitals and above.
Description
[technical field]
The present invention relates to a kind of test kit, specifically about a kind of carcinoma of prostate early stage hybridization in situ detection kit and detection method and application.
[background technology]
The data that provides according to domestic and international authoritative institution, the newly-increased number 1,700,000 of the annual cancer of China, death toll nearly 1,600,000, the patient 6,000,000, the annual newly-increased cancer patients 8,000,000 in the whole world, death toll is near 8,000,000, and the patient has 8,400 ten thousand people approximately, to double to the above number of the year two thousand twenty, this is one group of fearful numeral.
An annual report has been done by how tame units such as U.S. sanitary research institute in 2005, cancer research institute, Disease Control and Prevention Center, " think that the mankind are failures in anticancer Great War ", that is to say that cancer mortality does not reduce, it lists and causes the Several Factors of anticancer Great War failure to be: 1. tumour cell heterogeneity; 2. tumor cell drug resistance; 3. cancer therapy drug mentality of designing imperfection etc.Simultaneously, also propose to examine closely again the measure of existing diagnosis and treatment cancer in this report.
The inventor finds that under study for action two major reasons in addition that cause cancer mortality not fallen are: can not accomplish real early diagnosis 1.; 2. the pathomechanism of Zhuan Yiing is unclear.Come diagnosing cancer according to traditional medical image and with other biochemistry (as protein marker) index, think that occupancy cancer piece is the diagnosis (littler asymptomatic sometimes sign) that belongs to early-stage cancer under 2 centimeters, this notion is worth conscientiously discussing.It is rigorous inadequately that 2 centimeters early stage these of following cancer pieces genus of medical imaging define science, from the cytology angle, 1 centimeter lump has 100,000,000 tumour cells approximately, its three-dimensional cell stack number of 2 centimeters lump is far above 200,000,000 tumour cells, produce and form 2 centimeters cancer piece to the mono-clonal cancer cells early stage from canceration, its pathology evolution process is quite long, may be more than 1 year or 2 years even 3 years, what be difficult to confirm is in this process, and lump is unique spot of cancer and independent focus.Confirm clinically: in case when forming lump, other cancer cells are moved to other position clonal growths by different approaches; In case behind the excision primary tumor, other organ recurrence kitchen ranges or multiple cancer piece kitchen range successively form or shift.Therefore, whether define in early days rigorous inadequately (some case clinically with the lump size below 2 centimeters, when finding primary lesion, find metastatic lesion simultaneously, not in the content of our statement), at this moment be late period, this is the true cause that causes cancer mortality not fallen.
Along with molecular biotechnology is perfect day by day, functional genomics, the deep expansion of research such as cancer genomics, so far, we might do more accurate early diagnosis on gene level, form (during mono-clonal) or break through vessel wall when shifting in early days at canceration early stage or cancer cells, just can accomplish that early prediction diagnoses.
In decades, PSA has epoch making significance in the diagnosis of prostate cancer and treatment.Yet more and more in the last few years low abundance PSA prostate cancers are diagnosed, and PSA more and more is under suspicion to the susceptibility and the specificity of prostate cancer diagnosis.Stamey etc. analyze discovery to 1317 routine prostate cancer radical cure patients, and compare in the period of the 1983-1988 with between 1999-2003: the rectal touch positive rate drops to 17% by 91%; Patient's mean age reduced to 59 years old by 64 years old; Tumor size is reduced to 2.4cm by 5.3cm; Mean P SA level is reduced to 8nh/ml by 25ng/ml; Prostate volume increases to 53g by 44g.The investigator thinks that the PSA prostate cancer is closely related in the period of the 1983-1988, and PSA is only relevant with hyperplasia of prostate (volume) in the period of the 1999-2003.Among Bader etc. the report 1493 routine prostate cancer radical correction patients, the patients with prostate cancer PSA level low (8ng/ml) of considerable part is arranged, and this part patient is difficult to discriminating with hyperplasia of prostate.Stearns ME in 2004 etc. adopt methods such as RT-polymerase chain reaction, DAN protein binding assay, immunoblotting to confirm that PCADM-1 is a prostate cancer dependent diagnostic marker 1.PCADM-1 only expresses at prostate cancer tissue, does not have at BPH, high classification prostatic intraepithelial neoplasm and seminal vesicle tissue and expresses, and does not all have expression in other tumour, and the intensity that PCADM-1 expresses strengthens (+1---+5) along with Gleasson scoring increase.Adopt the enzyme linked immunological adsorption method to detect urine, the result shows, PCADM-1 is a tumor marker in the urine of prostate cancer specific.They show the comparative studies result of PCADM-and blood-serum P SA in 533 routine patients (comprise prostate cancer, BPH, urinary tract symptom patient and the normal control are arranged) urine, urine PCADM-1 detection sensitivity is 79%, specificity is 83%, and blood-serum P SA detection sensitivity＜50% specificity is 55%.
At present the high flux gene chip technology is all adopted in the research of PCADM-1 gene, and these methods are used for the scientific research aspect more, the incompatibility clinical application, particularly Ge Xinghua China's present stage condition that is applied in is still immature.Detection technique according to existing literature data PCADM-1 gene is not appeared in the newspapers.
Hybridization in situ technique (in situ hybridization) combines molecular biology and cytochemistry technology, is probe with the nucleic acid molecule of mark, in the technology of histocyte in situ detection specific nucleic acid molecule.Its principle is to make the nucleic acid strand (being probe) that contains distinguished sequence, process mark, under optimum conditions with histocyte in the complementary nucleic acid strand be that target nucleic acid is hybridized, with radioautograph or immunocytochemistry label probe is surveyed again, thereby shown special DNA or RNA molecule at cell in-situ.
Chinese patent literature CN1556221 discloses " IC53 gene and associated products diagnosis thereof and the purposes of treatment colorectal carcinoma and a kind of test kit of diagnosing colon cancer ".Chinese patent literature CN1769485 discloses " rickettsial in situ hybridization detection method of Pinna(Atrina)pectinate pathogeny and test kit thereof ".Chinese patent literature CN1556410 discloses " a kind of detection kit of fish virus and detection method thereof ".Chinese patent literature CN1680597 discloses " a kind of PCR kit for fluorescence quantitative that is used for detection by quantitative hepatitis C virus (HCV) ".Chinese patent literature CN2918435 discloses " a kind of oligonucleotide chip and test kit that detects obesity-related gene SNP ".But, do not appear in the newspapers about the hybridization in situ detection kit and the detection technique thereof of PCADM-1 gene.
[summary of the invention]
Technical problem to be solved by this invention is, the early stage hybridization in situ detection kit of a kind of carcinoma of prostate and detection method and application are provided, and can detect early prostate cancer, perhaps can predict the transfer and relapse situation early after treatment.
In order to address the above problem, the invention provides, the application of hybridization in situ detection kit in the early stage disease medicament of preparation detection carcinoma of prostate that a kind of carcinoma of prostate is early stage, described test kit comprises hybridization probe, marker, described hybridization probe sequence is shown in SEQ ID NO.1.(need to prove in the SEQID NO.1 sequence that base can be g or c or t in the 126th.Base can be g or c or t in the 391st.Base can be g or c or t in the 662nd.)
The PCADM-1 gene order is seen SEQ ID NO.1, and the nucleotide sequence length of PCADM-1 gene is 865bp, and CDS is 1 ... 865bp.
As optional technical scheme, the RNA sequence of described hybridization probe sequence shown in SEQ ID NO.1.
As optional technical scheme, described marker is selected from radionuclide or non-radioactive marker.
As optional technical scheme, described radionuclide is selected from
3H,
35S,
125I or
32A kind of among the P.
As optional technical scheme, described non-radioactive marker is selected from a kind of in vitamin H, digoxin, alkaline phosphatase, horseradish peroxidase or the fluorescein.
As optional technical scheme, described non-radioactive marker is preferably from digoxin.
As optional technical scheme, described test kit also comprises synergistic agent, and described synergistic agent is the alkaline phosphatase enzyme antibody.
The present invention also provides a kind of carcinoma of prostate early stage hybridization in situ detection kit, comprises hybridization probe, marker, and described hybridization probe sequence is shown in SEQ ID NO.1, and described marker is selected from radionuclide or non-radioactive marker.
The present invention also provides a kind of in situ hybridization detection method of PCADM-1 gene, and this method may further comprise the steps:
A, the hybridization probe in the test kit is contacted with RNA to be measured in the substrate, form hybridization complex;
The hybridization complex that b, detection a step obtain.
As optional technical scheme, the condition that forms hybridization complex in a step is: the temperature of nucleic acid hybridization is 42 ℃; The time of nucleic acid hybridization is 16-24 hours, and described substrate is selected blood cell sample or histocyte sample for use.
Detection kit of the present invention is to adopt nucleic acid hybridization technique and groupization immunization method to combine, with the PCADM-1 gene is detected object, synthesising probing needle is the DNA or the RNA sequence of PCADM-1 gene, and the substrate of detection is the expression amount of blood of human body sample white corpuscle or histiocytic RNA.The display packing of hybridization in situ technique can provide the sxemiquantitative or the quantitative expression deciding degree of PCADM-1 gene.Judge above expression of gene amount according to the immunohistochemical methods colour developing of hybridization back, normal people PCADM-1 gene is not expressed, and does not promptly develop the color, and the PCADM-1 gene is at prostate cancer patient high expression level.
The component of diagnostic kit of the present invention is by hybridization probe, hybridization solution, developer, compositions such as synergistic agent.The nucleic acid hybridization principle of this test kit is that the molecular biology insider all knows, and the concrete operations step is to carry out quantitative analysis, result's report under sample disposal, prehybridization, hybridization, immunohistochemical staining, the mirror, and wherein Za Jiao concrete steps comprise:
Instrumentation:
1). sample to be measured is put into reactive tank;
2). instrument discards liquid automatically, adds Digestive system automatically;
3). instrument discards liquid automatically, and the back is fixing automatically;
4). instrument discards liquid automatically, automatically prehybridization (42 ℃);
5). instrument discards liquid automatically, cleans automatically;
6). instrument discards liquid automatically, automatically hybridization (42 ℃);
7). instrument discards liquid automatically, cleans automatically;
8). instrument discards liquid automatically, and automatic and DIG antibody is cultivated (room temperature);
9). instrument discards liquid automatically, cleans colour developing automatically;
10). take out the mounting microscopy.
The invention has the advantages that:
1, test kit provided by the invention has characteristics highly sensitive, high specificity.
2, detection method of the present invention is convenient and simple for operation, can be widely used and promoted in Municipal Hospitals.Overcome and at present the high flux gene chip method has all been adopted in the research of PCADM-1 gene, and these methods are used for the scientific research aspect, the defective of incompatibility clinical application more.
3, clinical meaning of the present invention is that more the early detection carcinoma of prostate takes place, and diagnostic kit of the present invention is with other detects the oncofetal protein mark clinically, and the medical imaging inspection has remarkable difference.The present invention can (canceration early stage or cancer cell multiplication) detect the PCADM-1 gene unconventionality expression on gene level, before occupancy carninomatosis kitchen range is not found in the medical imaging inspection, and before not producing unusually early than PSA carcinoma of prostate biochemical indicator, also do not form before the tumour, can accomplish the information acquisition of above abnormal gene expression early, predict for real early diagnosis of clinical prostate cancer sufferer and treatment back transfer and relapse early.So just might implement early diagnosis, early prevention, the early treatment of prostate cancer, might from the source, thoroughly effect a radical cure the cancer foul disease.
4, carcinoma of prostate is more early stage, susceptibility is better than detecting with other kit gene to detect carcinoma of prostate with the PCADM-1 kit gene.The present invention adopts the mRNA of nucleic acid hybridization in situ technology for detection PCADM-1 or DNA is more early stage than the albumen of the PCADM-1 of urine, susceptibility is better.
[description of drawings]
Fig. 1 is carcinoma of prostate patient P CADM-1 overexpression figure in the embodiment of the invention.
Fig. 2 is normal people PCADM-1 figure in the embodiment of the invention.
[embodiment]
Below in conjunction with figure the early stage hybridization in situ detection kit of a kind of carcinoma of prostate provided by the invention and the embodiment of detection method and application thereof are elaborated.
Embodiment 1
The hybridization in situ detection kit that a kind of carcinoma of prostate is early stage comprises hybridization probe, marker, synergistic agent, and wherein, described hybridization probe sequence is shown in SEQ ID NO.1.The hybridization probe digoxigenin labeled.Other liquid and sample in the test kit are composed as follows:
Digestive system 100 μ l/ manage 1 pipe/box colourless transparent liquid
Protection liquid 100 μ l/ pipe 1 pipe/box colourless transparent liquid
Prehybridization solution 1300 μ l/ manage 2 pipe/box colourless transparent liquids
Justice hybridization solution 10 μ l/ pipe 1 pipe/box colourless transparent liquid
Antisense hybridization solution 10 μ l/ manage 1 pipe/box colourless transparent liquid
Confining liquid 1000 μ l/ manage 1 pipe/box colourless transparent liquid
Alkaline phosphatase enzyme antibody 1 μ l/ manages 1 pipe/box colourless transparent liquid
Developer A 175 μ l/ manage 1 pipe/box yellow liquid
Developer B 320 μ l/ manage 1 pipe/box colourless transparent liquid
Light yellow or the colourless transparent liquid of damping fluid I 10x 90ml/ bottle 1 bottle/box
Light yellow or the colourless transparent liquid of damping fluid II 10x 80ml/ bottle 1 bottle/box
Light yellow or the colourless transparent liquid of damping fluid III10x 20m/ bottle 3 bottle/boxes
Light yellow or the colourless transparent liquid of damping fluid IV 10x 90ml/ bottle 1 bottle/box
Stationary liquid 90ml/ bottle 1 bottle/box colourless transparent liquid
6/box of positive control sample
Mentioned reagent composition explanation: (all reagent are available from SIGMA)
1, Digestive system: the 20mg/ml Proteinase K, the 100mg Proteinase K adds DEPC-H
2O 5ml;
2, the glycine of protection liquid: 0.2g adds 1 * damping fluid I of 1ml;
3, prehybridization solution: 1 * damping fluid II7.5ml
50×D3ml
10mg/ml?yest?t-RNA?750ul
11mg/ml?SALMON?TESTES?DNA?682ul
0.04M?EDTA?3ml
50％?formamide?15ml
4, the bloking of confining liquid: 0.03g (buying from Roche Holding Ag) adds 1ml1 * damping fluid III;
5,10x damping fluid I:(PH7.1-7.4)
NaCl?80g
Na
2HPO
4.12H
2O?360g
KCl?2g
KH
2PO
4?2g
Add tri-distilled water to 1l, and autoclaving;
6,10x damping fluid II:(PH7.0)
NaCl?175.3g
Trisodium Citrate 88.2g
Several of HCl
Add tri-distilled water to 1l, and autoclaving;
7, damping fluid III:(PH7.9)
Tris 121.1g
NaCl 87.66g
About HCl 60ml
Add tri-distilled water to 1l, and autoclaving;
8, damping fluid IV:
1M Tris-HCl (PH9.5): Tirs121.1g adds about HCl3ml, adds water 900ml, transfers PH to 9.5, adds water to 1l, and autoclaving;
1M NaCl:NaCl58.44 adds water to 1l, and autoclaving;
0.5M MgCl
2: 101.65g MgCl
2.6H
2O adds water to 1l, and autoclaving;
9, stationary liquid: Paraformaldehyde 96 40g adds 1 * damping fluid I to 1l, and heat (about 50-60 degree) is stirred to dissolving a little;
10, developer A:NBT1g adds 70%DMF11.44ml;
11, developer B:BCIP 1g adds 100%DMF30ml.
Test kit of the present invention can many person-portions use or person-portion use.
Embodiment 2
A kind of in situ hybridization detection method of PCADM-1 gene and test kit thereof are used
One, sample disposal
1, with the centrifuge tube of 10ml, dress 4.5ml lymphocyte separation medium, again the 3ml anticoagulation is slowly added contain lymphocyte separation medium (blood: in the centrifuge tube of lymphocyte separation medium=1:1.5), the centrifugal 10min of 2000r/min;
2, draw the middle layer white corpuscle to another centrifuge tube, in this pipe, add 1 * damping fluid I of about twice again, mixing, the centrifugal 10min of 1500g/min;
3, abandon supernatant. precipitation adds 1 * damping fluid I of about twice, mixing, the centrifugal 10min of 1500g/min;
4, abandon supernatant, and test tube mouth excess liquid is gone with the tissue suction.Again precipitation is made suspension, drop in push jack on the slide, seasoning.(hospital with good conditionsi can use the pelleter film-making.) 3ml blood, can do 4 slice, thin pieces;
5, use the 40ml4% stationary liquid, in glass jar, fixedly 30min uses 1 * damping fluid I to wash 5min again.Every cylinder can be put 16;
6, sample can be kept at-20 ℃, or continues to do experiment.
Two, reagent in the test kit is mixed with working concentration
1,10 * damping fluid I is diluted to 1 * damping fluid I with tri-distilled water by 1:10;
2,20 * damping fluid II is diluted to 2 * damping fluid II with tri-distilled water by 1:10;
Be diluted to 0.2 * damping fluid II by 1:100; Be diluted to 0.1 * damping fluid II by 1:200;
3,10 * damping fluid III is diluted to 1 * damping fluid III with tri-distilled water by 1:10;
4,10 * damping fluid IV with tri-distilled water by 1:10 be diluted to * damping fluid IV (get 1#, 2#, each 10ml of 3#, add water to 100ml both can).
Three, experimental procedure:
1, gets two of every person's samples to be checked, two of (other two give over to check with) and positive control samples (test at every turn and do a pair of positive control);
2, in glass jar, add Digestive system (Digestive system 100ul adds 1 * damping fluid 199.9ml, is working concentration) 20ml.37 ℃ of water-bath preheatings 10 minutes.Put 16 slides into, handle 12min, use 1 * damping fluid I to wash 5min again for 37 ℃;
3, wash 10min with 0.2% protection liquid (protection liquid 1ml adds 1 * damping fluid I99ml and is working concentration), tri-distilled water is washed 5min, and above process is all carried out at glass jar.The slide seasoning;
4, slide is put into the box of preserving moisture, add prehybridization solution 20ul/ sheet. covered, the lid box of tightly preserving moisture is placed in 42 ℃ of constant water bath box more than the 3h;
5, take out slide, discard cover glass, slide is put into glass jar, with 70%, 90%, 95% ethanol is respectively washed 2min, seasoning;
6, slide is put into the box of preserving moisture, two of every patient specimens, one adds just hybridization solution 20ul/ sheet, and another adds antisense hybridization solution 20ul/ sheet. and covered, the lid box of tightly preserving moisture is placed on 16-24h in 42 ℃ of constant water bath box;
7, take out slide, discard cover glass, slide is put into glass jar
In 42 ℃ of constant water bath box, wash twice, each 15min with 2 * damping fluid II
In 42 ℃ of constant water bath box, wash once each 15min with 0.2 * damping fluid II
In 42 ℃ of constant water bath box, wash twice, each 15min with 0.1 * damping fluid II;
8, wash 30s with 1 * damping fluid III, take out slide, seasoning;
9, slide is put into the box of preserving moisture, add 0.5%l confining liquid (the 1ml confining liquid adds 5ml1 * damping fluid III) 100ul/ sheet, cover the box of tightly preserving moisture, at room temperature act on 30min;
10, take out slide, III washes 30s with 1 * damping fluid, seasoning;
11, slide is put into the box of preserving moisture, add alkaline phosphatase enzyme antibody (adding 1.8ml1 * damping fluid III) 100ul/ sheet, cover the box of tightly preserving moisture and at room temperature act on 30min;
12, take out slide, wash 3 times, each 15min with 1 * damping fluid III;
13,1 * damping fluid IV washes 2min, adds developer (developer A73.3ul, developer B157.5ul are added among 30ml1 * damping fluid IV, mixing), more than the room temperature lucifuge 12h;
14, wash 5min with tri-distilled water, seasoning, (add with glycerine 10% 1 * damping fluid I mixing) mounting microscopy.
Four, the result judges
100-300 cell of counting calculates the per-cent of catching the purple cell under light microscopic.
What the positive control sample added the antisense hybridization solution should catch purple more than 80%.
All add the negative internal reference of just hybridization solution should be colourless.
Carcinoma of prostate patient P CADM-1 overexpression figure sees Fig. 1.Normal people PCADM-1 figure sees Fig. 2.
The cDNA of digoxigenin labeled, RNA and oligonucleotide probe, not only probe has a biotin labeling advantage, also having overcome biotin labeled probe is organized the endogenous vitamin H to do shortcomings such as sorrow in the crossover process in position), this hybridization probe and the leukocytic RNA nucleic acid to be measured of blood of human body are hybridized, method with immunohistochemical methods develops the color again, under light microscopic, observe existence and the location of mRNA,, judge the expression amount of goal gene according to painted cell count.
The inventive method is a nucleic acid hybridization in situ technology commonly used at present, this method is by detecting the PCADM-1 gene expression amount in the substrate cell, be used for determining whether prostate cancer takes place, clinical study shows that the PCADM-1 gene is the specific gene of prostate cancer, and the PCADM-1 gene is not expressed in the normal people, in the prostate cancer patient, express only, in case PCADM-1 genetic expression illustrates that carcinoma of prostate takes place, thus the diagnostic message of acquisition prostate cancer.
Embodiment 3
Detect carcinoma of prostate and detect contrast experiment between the carcinoma of prostate with the PCADM-1 kit gene with PSA, AMACR kit gene.
The low prostate cancer of expressing of more and more clinically in the last few years PSA albumen is diagnosed, and susceptibility and the specificity to PSA marker diagnosing prostate cancer more and more is under suspicion clinically.PCADM-1 is the prostate cancer dependent diagnostic marker of finding recently 1.PCADM-1 only expresses at prostate cancer tissue, does not have at BPH, high classification prostatic intraepithelial neoplasm and seminal vesicle tissue and expresses, and does not all have expression in other tumour, and the intensity that PCADM-1 expresses strengthens (+1---+5) along with Gleasson scoring increase.Specificity, susceptibility, accuracy for scientific evaluation PSA, AMACR gene and each comfortable prostatic cancer early diagnosis of PCADM-1 gene.We use the method for parallel test, detect the mRNA of PSA, AMACR and PCADM-1 simultaneously, detection technique adopts the nucleic acid hybridization in situ technology, with the peripheral blood or the prostata tissue sample of same routine patients with prostate cancer, detect the mRNA (carrying out same procedure and step and reagent that PCADM-1 gene hybridization in situ technology is all adopted in nucleic acid hybridization in situ, immunohistochemical staining, mirror numeration down, report as a result etc.) of PCADM-1 gene and PSA, AMACR gene simultaneously.Find the PCADM-1 gene in the prostate cancer patient expression amount than PSA, AMACR gene expression amount height same prostate cancer patient.(see Fig. 3, Fig. 4, Fig. 5) result shows, the specificity of PCADM-1 gene pairs prostatic cancer early diagnosis, susceptibility, accuracy are better than PSA, AMACR gene, in situ hybridization genetic expression figure shows, PCADM-1 expression of gene amount is 70%, and PSA expression of gene amount is 50%, and the AMACR gene expression amount is 60%.The PCADM-1 gene is expressed in carcinoma of prostate only, and the early stage index that he makes in prostate cancer diagnosis has very important clinical meaning.The diagnostic techniques of possible substituting PS A marker.
The above only is a preferred implementation of the present invention; should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the principle of the invention; can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
SEQUENCE?LISTING
＜110〉Rui bends biotechnology (Shanghai) Co., Ltd.
＜120〉early stage hybridization in situ detection kit and detection method and the application of a kind of carcinoma of prostate
<130>/
<160>1
<170>Patent?In?vers?ion3.1
<210>1
<211>865
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<400>1
Claims (7)
1. the application of hybridization in situ detection kit in preparation detection early prostate cancer disease drug that carcinoma of prostate is early stage, described test kit comprises hybridization probe, marker, described hybridization probe sequence is shown in SEQ ID NO.1.
2. application according to claim 1 is characterized in that: described marker is selected from radionuclide or non-radioactive marker.
3. application according to claim 2 is characterized in that: described radionuclide is selected from
3H,
35S,
125I or
32A kind of among the P.
4. application according to claim 2 is characterized in that: described non-radioactive marker is selected from a kind of in vitamin H, digoxin, alkaline phosphatase, horseradish peroxidase or the fluorescein.
5. application according to claim 4 is characterized in that: described non-radioactive marker is preferably from digoxin.
6. application according to claim 1 is characterized in that: described test kit also comprises synergistic agent, and described synergistic agent is the alkaline phosphatase enzyme antibody.
7. the hybridization in situ detection kit that carcinoma of prostate is early stage comprises hybridization probe, marker, it is characterized in that, described hybridization probe sequence is shown in SEQ ID NO.1, and described marker is selected from radionuclide or non-radioactive marker.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100422578A CN101469348B (en) | 2008-08-29 | 2008-08-29 | In situ hybridization detection kit for early carcinoma of prostate, detecting method and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100422578A CN101469348B (en) | 2008-08-29 | 2008-08-29 | In situ hybridization detection kit for early carcinoma of prostate, detecting method and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101469348A CN101469348A (en) | 2009-07-01 |
| CN101469348B true CN101469348B (en) | 2011-07-20 |
Family
ID=40827153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100422578A Active CN101469348B (en) | 2008-08-29 | 2008-08-29 | In situ hybridization detection kit for early carcinoma of prostate, detecting method and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101469348B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102443641A (en) * | 2011-12-19 | 2012-05-09 | 苏州福英基因科技有限公司 | Various early-stage cancer pathology evolution MICRORNA-16 level in situ hybridization detection kit, detection method thereof and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1367386A (en) * | 2001-12-08 | 2002-09-04 | 云南大学 | Method for detecting total PSA value and total PSA gray zone value in whole blood or serum of human body and test paper for carcinoma of prostate |
| WO2003094844A2 (en) * | 2002-05-07 | 2003-11-20 | Philadelphia Health And Education Corporation(D/B/A Mcp Hahnemann University) | Prostate cancer-related compositions, methods, and kits based on dna macroarray proteomics platforms |
| CN1715921A (en) * | 2005-06-17 | 2006-01-04 | 吉林大学 | Use of human RGPR protein in preparing prostatic cancer diagnostic reagent kit |
-
2008
- 2008-08-29 CN CN2008100422578A patent/CN101469348B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1367386A (en) * | 2001-12-08 | 2002-09-04 | 云南大学 | Method for detecting total PSA value and total PSA gray zone value in whole blood or serum of human body and test paper for carcinoma of prostate |
| WO2003094844A2 (en) * | 2002-05-07 | 2003-11-20 | Philadelphia Health And Education Corporation(D/B/A Mcp Hahnemann University) | Prostate cancer-related compositions, methods, and kits based on dna macroarray proteomics platforms |
| CN1715921A (en) * | 2005-06-17 | 2006-01-04 | 吉林大学 | Use of human RGPR protein in preparing prostatic cancer diagnostic reagent kit |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101469348A (en) | 2009-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101993926A (en) | In-situ hybridization detection kit for MCM2 genes and detection method and application thereof | |
| CN101469351B (en) | Comprehensive detection kit for disgonosis, metastasis and recurrence of early prostate cancer, and use | |
| CN101386889A (en) | Kit for AMACR gene hybridization in situ, detection method and use thereof | |
| CN101363046A (en) | Kit for broad spectrum cancer hybridization in situ, detection method and application thereof | |
| CN101363047A (en) | Kit for TTF1 gene hybridization in situ, detection method and application thereof | |
| CN101363051A (en) | Kit for GALECTIN-3 gene hybridization in situ, detection method and application thereof | |
| CN101469348B (en) | In situ hybridization detection kit for early carcinoma of prostate, detecting method and use thereof | |
| CN101988095A (en) | In-situ hybridization detection kit for SCCA1 genes and detection method and application thereof | |
| CN101469350B (en) | Comprehensive detection kit for early carcinoma of prostate, detecting method and use thereof | |
| CN101363050B (en) | Kit for CD326 gene hybridization in situ, detection method and application thereof | |
| CN101363048B (en) | Kit for NKX2-8 gene hybridization in situ, detection method and application thereof | |
| CN101429542A (en) | Hybridization in situ detection kit for VMP1 gene, detection method and uses thereof | |
| CN101469349A (en) | In situ hybridization detection kit for lung cancer , detecting method and use thereof | |
| CN101386888B (en) | Kit forEvi-1 gene hybridization in situ | |
| CN101993927A (en) | LAMB1 gene in-situ hybridization detection kit and detection method and use thereof | |
| CN101429548A (en) | DLK1 gene nucleic acid hybridization in situ detection kit, detection method and uses thereof | |
| CN101993920A (en) | In-situ hybridization detection kit for Survivin genes and detection method and application thereof | |
| CN101363053A (en) | Kit for tMK gene hybridization in situ, detection method and application thereof | |
| CN101363049A (en) | Kit for early cancer metastasis hybridization in situ, detection method and application thereof | |
| CN101993917A (en) | Cdc2 gene in-situ hybridization detection kit and detection method and use thereof | |
| CN101328499B (en) | In situ hybridization detection reagent box of RhoGDI2 gene, detection method and use thereof | |
| CN101429551B (en) | Detection kit for HMG-1 gene nucleic acid hybridization in situ, detection method and uses thereof | |
| CN101429555A (en) | Detection kit for early hybridization in situ of pancreatic cancer, detection method and uses thereof | |
| CN101429554B (en) | Detection kit for HCCR gene nucleic acid hybridization in situ, detection method and uses thereof | |
| CN101993944A (en) | In-situ hybridization testing kit of ALDH1 gene and testing method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: SUZHOU FUYING GENE TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: RUIQU BIOTECHNOLOGY (SHANGHAI) CO., LTD. Effective date: 20110429 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201108 ROOM 426, BUILDING 4, NO. 728, GUANGHUA ROAD, MINHANG DISTRICT, SHANGHAI TO: 215132 ROOM 307, BUILDING A2, BIOBAY, NO. 218, XINGHU STREET, SUZHOU INDUSTRIAL PARK |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20110429 Address after: 215132 Suzhou Industrial Park BioBAY Xinghu Street No. 218 building A2 room 307 Applicant after: Suzhou Fuying Gene Technology Co.,Ltd. Address before: 201108 room 4, building 728, Guanghua Road, 426, Shanghai, Minhang District Applicant before: Ruiqu Biotechnology (Shanghai) Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: LI XUEYING Free format text: FORMER OWNER: SUZHOU FUYING GENE TECHNOLOGY CO., LTD. Effective date: 20150727 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150727 Address after: 704, room 2, unit 1, B District, Oriental Pearl District, Liandu District, Zhejiang, Lishui 323000, China Patentee after: Li Xueying Address before: Suzhou City, Jiangsu Province, Suzhou Industrial Park 215132 Xinghu Street No. 218 BioBAY building A2 room 307 Patentee before: Suzhou Fuying Gene Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20201125 Address after: Room 631, No. 318, Taizhou Road, Zhejiang Province Patentee after: Taizhou hehe Biotechnology Co., Ltd Address before: 704, room 2, unit 1, B District, Oriental Pearl District, Liandu District, Zhejiang, Lishui 323000, China Patentee before: Li Xueying |
|
| TR01 | Transfer of patent right |